Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis (PRNewswire) - Oct 22, 2026 - "The approval is supported by positive results from a pivotal Phase 3 clinical study conducted at 27 centers in China. The main study population was patients with generalized myasthenia gravis who were positive for acetylcholine receptor antibodies (AChR-Ab) or muscle-specific tyrosine kinase antibodies (MuSK-Ab)."
China approval • Immunology • Myasthenia Gravis
|